Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherInflammation, Immunopharmacology, and Asthma

MF63 {2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)isophthalonitrile}, a selective microsomal prostaglandin E synthase 1 inhibitor, relieves pyresis and pain in preclinical models of inflammation

Daigen Xu, Steven E Rowland, Patsy Clark, Andre Giroux, Bernard Cote, Sebastien Guiral, Myriam Salem, Yves Ducharme, Richard W Friesen, Nathalie Methot, Joseph Mancini, Laurent Audoly and Denis Riendeau
Journal of Pharmacology and Experimental Therapeutics June 4, 2008, DOI: https://doi.org/10.1124/jpet.108.138776
Daigen Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven E Rowland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patsy Clark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andre Giroux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Cote
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastien Guiral
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myriam Salem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Ducharme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard W Friesen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Methot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Mancini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Audoly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Riendeau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 387 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 387, Issue 1
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MF63 {2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)isophthalonitrile}, a selective microsomal prostaglandin E synthase 1 inhibitor, relieves pyresis and pain in preclinical models of inflammation
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherInflammation, Immunopharmacology, and Asthma

MF63 {2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)isophthalonitrile}, a selective microsomal prostaglandin E synthase 1 inhibitor, relieves pyresis and pain in preclinical models of inflammation

Daigen Xu, Steven E Rowland, Patsy Clark, Andre Giroux, Bernard Cote, Sebastien Guiral, Myriam Salem, Yves Ducharme, Richard W Friesen, Nathalie Methot, Joseph Mancini, Laurent Audoly and Denis Riendeau
Journal of Pharmacology and Experimental Therapeutics June 4, 2008, DOI: https://doi.org/10.1124/jpet.108.138776

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherInflammation, Immunopharmacology, and Asthma

MF63 {2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)isophthalonitrile}, a selective microsomal prostaglandin E synthase 1 inhibitor, relieves pyresis and pain in preclinical models of inflammation

Daigen Xu, Steven E Rowland, Patsy Clark, Andre Giroux, Bernard Cote, Sebastien Guiral, Myriam Salem, Yves Ducharme, Richard W Friesen, Nathalie Methot, Joseph Mancini, Laurent Audoly and Denis Riendeau
Journal of Pharmacology and Experimental Therapeutics June 4, 2008, DOI: https://doi.org/10.1124/jpet.108.138776
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PAR2 inhibition reduces neuroinflammation
  • First-in-Human Phase 1 Trial with KPL-404
  • CCR6 Selective Antagonist in Homeostasis and Inflammation
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics